Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)

Pre-clinicalCompleted

1 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Growth Hormone (GH) Deficiency

Conditions

Growth Hormone (GH) Deficiency, Short Stature Homeobox Containing Gene (SHOX) Deficiency, SHOX Deficiency-related Disorder, Non-GH-deficient Growth Disorders

Trial Timeline

Apr 1, 1999 → Sep 1, 2015

NCT ID

NCT01088412

About Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)

Somatropin (recombinant deoxyribonucleic acid [rDNA] origin) is a pre-clinical stage product being developed by Eli Lilly for Growth Hormone (GH) Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT01088412. Target conditions include Growth Hormone (GH) Deficiency, Short Stature Homeobox Containing Gene (SHOX) Deficiency, SHOX Deficiency-related Disorder.

What happened to similar drugs?

11 of 20 similar drugs in Growth Hormone (GH) Deficiency were approved

Approved (11) Terminated (1) Active (9)

✅PEG-somatropinSun PharmaceuticalApproved

✅PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved

✅Saizen® solution for injection (referred as Saizen®)MerckApproved

✅Saizen + SaizenMerckApproved

✅EverolimusNovartisApproved

✅somatropin + somatropin + somatropinNovo NordiskApproved

✅somatropin + placeboNovo NordiskApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01088412	Pre-clinical	Completed	Apr 1, 1999	Sep 1, 2015	Growth Hormone (GH) Deficiency

Competing Products

20 competing products in Growth Hormone (GH) Deficiency

See all competitors

Product	Company	Stage	Hype Score
Somatropin	Eli Lilly	Phase 3	40
HER3-DXd	Daiichi Sankyo	Pre-clinical	26
Erlotinib	Astellas Pharma	Phase 2	27
radio-labeled naquotinib + naquotinib	Astellas Pharma	Phase 1	21
pegylated Somatropin + pegylated Somatropin + Jintropin AQ	Sun Pharmaceutical	Phase 2	35
PEG-somatropin	Sun Pharmaceutical	Approved	39
PEG-somatropin + PEG-somatropin	Sun Pharmaceutical	Approved	39
PEG-somatropin	Sun Pharmaceutical	Phase 3	40
Somatropin + Somatropin	Eli Lilly	Phase 3	40
Somatropin + Somatropin	Eli Lilly	Phase 3	40
somatropin, rDNA origin, for injection	Eli Lilly	Phase 3	40
Sterile becaplermin gel vs. sterile placebo gel treatment 1	Johnson & Johnson	Pre-clinical	26
ABT-414	AbbVie	Pre-clinical	26
Saizen® A + Saizen® B	Merck	Phase 3	40
Saizen® solution for injection (referred as Saizen®)	Merck	Approved	43
Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)	Merck	Phase 3	40
Saizen + Saizen	Merck	Approved	43
Miransertib	Merck	Phase 2	39
Miransertib	Merck	Phase 1/2	24
ARX201 + ARX201 + ARX201	Merck	Phase 2	35